Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids

2.1 Relugolix–estradiol–norethisterone acetate (Ryeqo, Gedeon Richter UK) is indicated for the 'treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age'.

2.2 The dosage schedule is available in the summary of product characteristics for relugolix–estradiol–norethisterone acetate.

2.3 The list price of relugolix–estradiol–norethisterone acetate is £72.00 for a 28‑pack of 40 mg/1 mg/0.5 mg tablets (excluding VAT; BNF online, accessed April 2022). The annual treatment cost is £939.21. Costs may vary in different settings because of negotiated procurement discounts.